News | Cardiac Diagnostics | September 13, 2016

New Position Statement Evaluates Role of ECG in Athletic Cardiovascular Screening

Statement acknowledges potential benefits of ECG screening but ultimately recommends personalized approach for individual athletes

AMSSM, American Medical Society for Sports Medicine, cardiovascular screening, athletes, position statement

September 13, 2016 — The American Medical Society for Sports Medicine (AMSSM) last week released a new position statement on cardiovascular pre-participation screening for athletes. The statement discusses current evidence and knowledge gaps while offering recommendations and future directions.

AMSSM formed a task force to address the controversial topic of cardiovascular screening in athletes and the potential addition of an electrocardiogram (ECG) to the standard history and physical examination. The position statement presents several new paradigm shifts in thinking about cardiovascular screening in athletes — namely a reassessment of the current standard, recognition of the differential risk of sudden cardiac arrest and death (SCA/D) in different athlete populations, a new framework to assist physicians when considering a screening ECG and respect for physician autonomy to choose the most appropriate screening strategy.

Developed by an expert panel of primary care sports medicine physicians representing all perspectives on cardiovascular screening, the statement provides a balanced assessment of the current evidence and knowledge gaps regarding cardiovascular screening in athletes. The position statement is concurrently being published in the Clinical Journal of Sport Medicine, the British Journal of Sports Medicine and Current Sports Medicine Reports.

The primary goal of cardiovascular screening in competitive athletes is to identify cardiac disorders at elevated risk of SCA/D and to reduce morbidity and mortality through individualized and disease-specific management. The current pre-participation history and physical examination, while pragmatic and widely practiced, is limited in its ability to identify athletes with conditions at risk for SCA/D.

ECG screening does offer enhanced detection of cardiac disorders at potential risk of SCA/D, but it also increases the potential for false-positive results and the associated downstream consequences. “Evidence suggests medical management can reduce the risk of sudden death for several of the cardiac disorders we are looking for. The question is whether we can accomplish early detection and proper management without causing undue harm,” said Jonathan Drezner, M.D., lead author and co-chair of the statement and an AMSSM past president. In choosing a screening strategy, sports medicine physicians should consider the individual risk of the athlete, physician expertise and available cardiology resources for accurate ECG interpretation and the secondary evaluation of ECG abnormalities, as well as their assessment that a particular screening strategy will provide more benefit than harm.

“In the absence of clear evidence, we must respect physician autonomy to implement the most appropriate screening strategy unique to their athlete population and community resources,” stated Fran O’Connor, M.D., MPH, also co-chair of the statement and an AMSSM past president. Widely practiced and accepted screening standards are not perfect and should undergo continual revision as new data emerges.

ECG screening is often framed as a choice between universal, mandatory screening or no screening at all. “A single, universal strategy or ‘one-size-fits-all’ model may not be appropriate for all athletes or all physicians,” Drezner added. Accordingly, AMSSM supports continued research in this area to validate the optimal strategies for reducing SCA/D in athletes.

For more information: www.journals.lww.com, www.bjsm.bmj.com

Related Content

The BardyDx Carnation Ambulatory Monitor (CAM) is a P-wave centric wearable ambulatory cardiac patch monitoring and arrhythmia detection device. 

The BardyDx Carnation Ambulatory Monitor (CAM) is a P-wave centric wearable ambulatory cardiac patch monitoring and arrhythmia detection device. 

News | Cardiac Diagnostics | July 29, 2021
July 29, 2021 — A recent clinical study from Overlake Medical Center utilizing the Bardy Diagnostics Carnation Ambula
The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

The FDA has cleared Angel Medical Systems' second-generation AngelMed Guardian device. The implantable cardiac device detects and warns patients if they are having an acute coronary syndrome (ACS) event, including silent heart attacks. The new, second-generation device is enhanced with ease-of-use adaptations and an updated, long life battery that could potentially double the life of the implanted device

News | Cardiac Diagnostics | July 01, 2021
July 1, 2021 — The U.S. Food and Drug Administration (FDA) has cleared the Angel Medical Systems Inc.
Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Detecting heart disease with OCT imaging of the eye.Getty Images

Ophthalmic optical coherence tomography (OCT) scan view of the macula in retina with vessels. Getty Images
 

News | Cardiac Diagnostics | March 08, 2021
March 8, 2021 — In a new study from Shiley Eye Institute at UC San Diego Health, researchers have identified a potent
Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia.

Alivecor's pocket ECG system allows consumers or cardiologists to record a single lead ECG strip on a smartphone. AI algorithms can determine if their ECG is normal or abnormal and identify the arrhythmia. 

News | Cardiac Diagnostics | March 03, 2021
March 3, 2021 — AliveCor recently announced a new collaboration with AstraZeneca to research new disease management s
A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images Health disparities in cardiovascular disease.

A study of more than 100 million Americans in 3,123 counties found a correlation between cardiac death and their level of income. Getty Images

News | Cardiac Diagnostics | February 02, 2021
February 2, 2021 — A new study has found in the U.S.
A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

A new study highlights the importance of continued public education regarding the risks of cigarette smoking and the failure of dual use with vaping to reduce cardiovascular risk. Getty Images

News | Cardiac Diagnostics | January 06, 2021
January 6, 2021 — Smoking traditional cigarettes in addition to using e-cigarettes results in harmful health effects
The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia.

The Mesuron Inc. Avalon-H90 uses magnetometers to detect myocarditis in patients without any physical contact. It uses ventricular repolarization dynamics analysis software to look for abnormalities. The vendor said it is more specific than using ECG. It detects the multidimensional dynamics of the electrical activity caused by differences in functions of electrical action potential of normal heart tissues and abnormal ones with hypoxia. 

News | Cardiac Diagnostics | October 06, 2020
October 6, 2020 — A new technology being developed by U.S.-based Mesuron Inc.
With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a costly tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. Amyloidosis Patient Registry  #Amyloidosis

With the advent and optimization of nuclear scintigraphy protocols using bone-avid radiotracers, cardiac amyloidosis caused by transthyretin protein (ATTR) can now be diagnosed noninvasively without a tissue biopsy. The radiotracer 99mTc-pyrophosphate (99mTc-PYP) binds to deposited ATTR amyloid fibrils in the myocardium and can be visualized using planar and SPECT imaging. This is Figure 2, showing how SPECT imaging allows the reader to distinguish between blood pool activity (ventricular cavity, etc) and myocardial activity and identify regional myocardial differences in radiotracer uptake.

News | Cardiac Diagnostics | March 05, 2020
March 5, 2020 — More than 300 patients have joined the Amyloidosis Patient Registry and it is now available to the en